The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer.
Adam J SchoenfeldChai BandlamudiJessica A LaveryJoseph MontecalvoAzadeh NamakydoustHira RizviJacklynn V EggerCarla P ConcepcionSonal PaulMaria E ArcilaYahya DaneshbodJason ChangJennifer L SauterAmanda BerasMarc LadanyiTyler JacksCharles M RudinBarry S TaylorMark T A DonoghueGlenn HellerMatthew D HellmannNatasha RekhtmanGregory J RielyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
SMARCA4 alterations can be divided into two clinically relevant genomic classes associated with differential protein expression as well as distinct prognostic and treatment implications. Both classes co-occur with KEAP1, STK11, and KRAS mutations, but individually represent independent predictors of poor prognosis. Despite association with poor outcomes, SMARCA4-mutant lung cancers may be more sensitive to immunotherapy.